Traduction de «formulate and present » (Anglais → Français) :

aid the formulation of prison and detention centre procedures | help with the formulation of correctional procedures | contribute to the formulation of correctional procedures | help with the formulation of prison and detention centre procedures

cosmetics formulation development chemist | skin care formulation chemist | cosmetic chemist | formulation development chemist

help determine context to present the work | propose context to present work | help determine context for presentation of work | help determine the context in which the work will be presented

Working formulation of non-Hodgkin lymphoma

audio-visual presentation [ audio visual presentation | audiovisual presentation | auditory and visual presentation | sound/vision presentation | audiovisual display | audio-visual display | audiovisual show ]

Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include sel ...[+++]f-report data, analysis of blood and other body fluids, characteristic physical and psychological symptoms, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

no card present fraud [ no card present | card-not-present fraud | card not present ]

formal presentation [ stage presentation | formal stage presentation | lecture ]

An extremely rare epithelial neoplasm of the liver and biliary tract which presents with heterogenous histological findings and not yet fully defined clinicopathological characteristics. Patients usually present with nonspecific signs and symptoms, s

A rare cancer of corpus uteri presenting as a large, polypoid, intraluminal mass with necrosis, composed of small to intermediate-size, relatively uniform, dyshesive cells displaying no differentiation. It usually presents with dysfunctional bleeding

The eSafety initiative launched in 2002 by the Commission and the motor vehicle industry [29] as part of the eEurope plan launched by the Heads of State at the Feira European Council in June 2001 has resulted in the formulation of recommendations and a number of actions at Community level which will shortly be presented by the Commission in a communication on information and communication technologies for intelligent vehicles.

The conclusions presented herein, as part of the Final Evaluation of the Safer Internet Action Plan (2003-2004), have been formulated by an independent, three-member Expert Panel.

This action seeks to design and roll-out a prospective study aiming to assess how NCPs can best formulate and present information to patients.

they are either the same or equivalent in the co-formulants present and the packaging size, material or form, in terms of the potential adverse impact on the safety of the product with regard to human or animal health or the environment.